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1. Introduction 
Myocarditis is a devastating cardiac disease causing death in children and young adults 
worldwide (Esfandiarei et al. 2008). The disease is clinically characterized by 
inflammation of the myocardium and degeneration of myocytes. Clinical symptoms of 
viral myocarditis range from flu-like and/or gastrointestinal illness to ventricular 
dysfunction ending commonly in heart failure. Acute disease is accompanied by multi-
organ abnormalities and presents mostly in neonates and young children. Chronic disease 
occurs in one third of patients and is likely a consequence of autoimmune-mediated 
myocardial injury and viral persistence. As cardiac myocytes are destroyed by virus 
and/or self-induced cytopathic immune effects, excessive repair or fibrosis of myocardial 
tissue impairs disease progression rather than protects the tissue from further damage. 
Fibrosis or scar tissue, can lead to abnormal ventricular architecture that inevitably leads 
to the disruption of its function. At this stage of disease, chronic myocarditis progresses to 
dilated cardiomyopathy and can eventually lead to congestive heart failure (Esfandiarei et 
al. 2008).  
The exact cause for myocarditis is still unknown though pathogen infections, 
hypersensitivity reactions, and systemic and autoimmune diseases are all likely contributing 
factors. It is suggested that acute viral myocarditis that progresses to chronic disease mirrors 
the clinical pathology observed with dilated cardiomyopathy patients and is likely the result 
of an inappropriate immune response after virus infection that leads to chronic 
inflammation and virus persistence (Escher et al. 2011).  
Tracking the incidence of myocarditis is challenging. It is difficult to determine the potential 
disease burden to populations since there is a range in clinical symptoms associated with 
disease and endomyocardial biopsy to diagnose disease is rarely practised (Blauwet et al. 
2010). Though mounting evidence of viral genomes recovered from chronic dilated 
cardiomyopathy patients provides some insight in to the potential burden of this 
devastating cardiac disease (Kuhl et al. 2005). Viral-induced myocarditis and dilated 
cardiomyopathy leads to a worse prognosis than other possible myocarditis/dilated 
cardiomyopathy etiological agents. Isolation of enteroviral RNA from endocardial biopsies 
of myocarditis and dilated cardiomyopathy patients renders these patients six times more 
susceptible to death after two years from diagnosis compared to virus-negative patients 
(Why et al. 1994). Sex is another contributing factor to disease susceptibility. Initially, it was 
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reported that men develop myocarditis twice as often as women and recent clinical work as 
supported this notion though the incidence is not quite as high as claimed in 1980 
(Woodruff 1980; Mason et al. 1995; Kuhl et al. 2003; Cooper 2009).  
Diagnosis and treatment of viral myocarditis is challenging due to the lack in specific 
clinical features and signature serological markers known for the acute phase of disease.  
The standard Dallas criteria that were typically used for diagnosis of myocarditis are not 
appropriate for determining viral or autoimmune myocarditis since they avoid the 
identification of inflammation or viral genome in the heart  (Aretz 1987; Aretz et al. 1987). A 
more appropriate set of guidelines was established in 1995 by the WHO, with a classification 
of cardiomyopathies requiring endomyocardial biopsy, histological Dallas criteria, 
immunohistochemistry and viral PCR amongst the criteria for diagnosis (Richardson et al. 
1996). Four stages of clinical disease in humans have been described since the implication of 
the 1995 WHO criteria: fulminant, subacute, chronic active and chronic persistent 
myocarditis. The first three stages involve mild to moderate dysfunction of the left ventricle, 
with the fourth, chronic persistent stage, characterized by normal ventricular function. Both 
chronic stages have ongoing inflammation with the development of scar tissue from 
myocardial damage. It is only during the chronic persistent stage that viral genome is 
detected from endomyocardial biopsy tissue  (Lieberman et al. 1991; Olsen 1993). The 
incidence of viral infection, specifically coxsackievirus B infection, in human myocarditis, 
originates from seroepidemiologic and molecular studies between the 1950s and 1990s and 
from observations of viral genomes in cardiac tissue more prevalently in dilated 
cardiomyopathy patients compared to valvular or ischemic cardiomyopathies.   
The true etiology and molecular pathogenesis responsible for viral myocarditis in humans 
remains unclear. Serological studies  and endomyocardial biopsies from myocarditis 
patients have associated  over 20 different viruses including coxsackieviruses, adenoviruses, 
cytomegaloviruses, parvoviruses, influenza viruses, and even human immunodeficiency 
viruses with the disease (Yajima et al. 2009; Blauwet et al. 2010).  Of all the viruses 
implicated, it is the enteroviruses, specifically coxsackievirus B, which show the most likely 
contribution. 
Coxsackievirus A and B are enteroviruses that are a part of the Picornaviridae family 
(Baboonian et al. 1997). They are human pathogens transmitted fecal-orally that cause 
enteric diseases (coxsackievirus A) as well as severe disease in the heart, pancreas, and 
central nervous system (coxsackievirus B) (Baboonian et al. 1997). Coxsackievirus A has 23 
different serotypes, whereas coxsackievirus B has six. The six coxsackievirus B serotypes can 
instigate a variety of diseases  including two very important autoimmune diseases: 
myocarditis and type I diabetes (Richer et al. 2009). It is also important to note that all 
coxsackievirus B serotypes are capable of triggering systemic disease in infants that can 
devastating lead to death (Esfandiarei et al. 2008).  Relevant to myocarditis is the 
coxsackievirus B serotype 3 (coxsackievirus B3). Coxsackievirus B3 has been linked to 
approximately 30% of new dilated cardiomyopathy cases per anum though data 
establishing a direct link between coxsackievirus B3 pathogenesis and the onset of 
myocarditis in patients is lacking (Huber et al. 1998). The B3 serotype has a 7.4-kb single-
stranded positive-sense RNA genome containing a VPg (3B) protein at the 5’ end. The 7-
methyl guanosine-like cap  influences replication and translation following virus entry 
(Flanegan et al. 1977). To gain entry in to a cell, coxsackieviruses interact with both 
coxsackievirus and adenovirus receptor (CAR) and decay accelerating factor (DAF) located 
both in the host cell membrane (Figure 1) (Pelletier et al. 1988).  
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Fig. 1. Tentative coxsackievirus life cycle. The general host and virus components suggested 
to contribute to production of new coxksackievirus: 1) Viral entry through binding 
coxsackievirus and adenovirus receptor (CAR) and decay accelerating factor (DAF), 2) 
Internalization and transport of viral particles to the Golgi and endoplasmic reticulum (ER) 
3) viral uncoating, 4) release of viral RNA, translation of RNA by ribosomes on the rough 
endoplasmic reticulum (ER) into viral polyprotein, 5) autocleavage of polyprotein into viral 
structural and functions proteins, 6) positive and negative strand RNA transcription to 
replicate viral genome, 7) release of viral genome in to the cytosol to encapsidate with 
structural proteins, 8) formation and release of viral progeny.    
Once the virus enters the cytosol and uncoats, its positive-sense genome is released in the 
cytosol for translation and later, transcription. As a polyprotein comprised of the virus 
proteins VP4, VP3, VP2, VP, 2A, 2B, 2C, 3A, 3B, 3C, and 3D emerges from translation at the 
rough endoplasmic reticulum (ER), it is cleaved into its respective structural and functional 
proteins. The virally encoded 3Dpol is a RNA-dependent RNA polymerase that transcribes 
viral positive-sense RNA in to negative-sense RNA strands that serve as intermediates for the 
transcription of multiple positive-sense RNA strands needed for new progeny virions. After 
synthesis, the newly generated positive-RNA strands are packaged in new virus particles 
formed by the newly generated structural and functional virus proteins. The new progeny 
viruses are then released via plasma membrane by a mechanism likely mediated by viral 
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protein 2B (van Kuppeveld et al. 1997; Esfandiarei et al. 2008).   Though many groups have 
identified key virus and host interactions throughout the coxsackievirus B life cycle, there still 
remains many stages unsolved. Nevertheless, the role of coxsackievirus B in the onset of 
myocarditis has been extensively studied thus far in animal models and cell culture systems. 
Here, we will discuss clinical and mouse studies that have investigated coxsackievirus-
induced myocarditis and the role of key immune players in disease pathogenesis.  
2. In vivo experimental systems 
Mice provide a model system to distinguish characteristics of disease between autoimmune 
myocarditis and viral myocarditis. Mice are advantageous models because they share 
similar genetics to humans, they are cost-effective in handling and breeding, many 
transgenic strains are available and they are responsive to cardiotropic viruses 
(Cunningham 2001; Fairweather et al. 2001; Esfandiarei et al. 2008). Coxsackievirus B3 has 
been detected in 30-50% of dilated cardiomyopathy patients, providing support for a 
coxsackievirus B3-induced myocarditis mouse model (Escher et al. 2011). Following a single 
dose of coxsackievirus B3, acute myocarditis, encephalomeningitis, hepatitis, and even 
pancreatitis can ensue. Severe systemic pathogenicity observed with coxsackievirus B3 
infection has also been related to the presence of sarcoma (Src) family kinase Lck (p56lck) 
(Liu et al. 2000). With coxsackievirus B3 infection, mice tend to either develop chronic 
dilated cardiomyopathy mirroring clinical disease after recovering from viral infection or 
mice die from severe cytopathic effects, thus making coxsackievirus B3-induced myocarditis 
an excellent yet challenging model to study (Liu et al. 2000). 
Studies with mice have demonstrated the significant contribution of the Th1 immune 
response to disease severity even though coxsackievirus B3 directly targets and destroys the 
myocardium.  The contribution of a Th1 response to viral myocarditis pathogenesis is 
supported by studies modulating and inhibiting immune components and improving 
cardiac damage and function (Jiang et al. 2008).  
Interestingly and in parallel with human myocarditis, male mice infected with 
coxsackievirus B3 experience acute myocarditis with greater severity compared to females. 
Greater disease severity in males has been linked to enhanced cardiac and splenic mast cell 
and macrophage TLR-4 expression at 12 hours post-infection (Frisancho-Kiss et al. 2006; 
Frisancho-Kiss et al. 2007). In males virally infected, signalling through cardiac TLR-4 
enhances the production of cardiac IL-1┚ and IL-18 and promotes a Th1 skewed immune 
response (Fairweather et al. 2003).  Also, male mice infected with coxsackievirus B3 harbour 
macrophages of a different phenotype and have more severe disease compared to infected 
female mice though viral replication is at similar levels in the heart (Frisancho-Kiss et al. 
2006; Frisancho-Kiss et al. 2007).  Moreover, genes relating to cholesterol metabolism in 
macrophages and to androgen receptor, which are known predictors for myocarditis, 
dilated cardiomyopathy and heart failure in male mice and humans, are upregulated 
considerably in spleens of male mice (Onyimba et al. 2011).  This not only affords support 
for a gender difference in the susceptibility to viral-myocarditis, but critically implicates the 
innate response in disease severity.  Furthermore, to bring male mice to the same 
immunological plane as female mice during myocarditis, Frisancho-Kiss et al removed the 
gonads from BALB/c mice and observed an increase in IL-4 production, the activation of 
macrophages and induction of regulatory T cells in the heart (Frisancho-Kiss et al. 2009).   
Myocarditis can be induced in female mice with TNF-┙ treatment on days 1 and 3 post 
coxsackievirus B3 infection (Huber 2010). The lack of disease susceptibility in females is 
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attributed to low mRNA and protein levels of TNF-┙ and IL-I┚ as well as reduced CD1d 
expression on splenic lymphocytes. CD1d is an important non-classical major 
histocompatibility complex antigen that can be regulated by TNF-┙ to induce myocarditis 
susceptibility in female mice (Huber 2010).  
Not only is susceptibility to developing myocarditis dictating by sex, but development of 
chronic disease depends on the mouse strain. A.BY/SnJ & SWR/J are susceptible mouse 
strains that can develop ongoing myocarditis, where viral RNA is detected within the 
myocardium. C57BL/6J & DBA/1J mice are resistant strains capable of eliminating virus 
just after the early acute phase of disease. Tomioka and colleagues investigated neutralizing 
antibodies and their role in virus-induced myocarditis and B-cell-mediated immunity using 
BALB/c mice (Esfandiarei et al. 2008). NK-deficient mice have been used to look at the role 
of natural killer (NK) cells in killing virus-infected cardiomyocytes  (Godeny et al. 1986). 
Perforin knockout mice inoculated with coxsackievirus B3 have also been used to describe 
the interplay of virus infection and lymphocyte infiltration in the myocytes and their effect 
on disease outcome (Godeny et al. 1987).  Interestingly, with coxsackievirus B3 infection in 
suckling, weaning and adolescent mice, coxsackievirus B3 replicates in the heart, pancreas, 
spleen, and brain and causes human disease-like symptoms. In fact, following IP injection, 
three distinct immunovirological phases of disease have been observed. 
In mice, coxsackievirus B3 can induce two forms of inflammatory heart disease, acute only 
or acute and chronic (biphasic) autoimmune disease (Horwitz et al. 2000; Cunningham 
2001; Fairweather et al. 2001). Interestingly, coxsackievirus B3 replication is mainly 
observed in the pancreas and to a lesser extent in the heart. In genetically susceptible 
mice, such as A/J2, Balb/c and NOD mice, chronic autoimmune myocarditis after 
coxsackievirus B3 infection is observed. Autoimmune myocarditis in mice presents as 
early as day 7 pi with inflammatory cell infiltration in the heart and the formation of 
multifocal inflammatory lesions. At this stage, autoantibodies (autoAbs) against heart 
antigens, like cardiac myosin (cardiac myosin), are seen. In NOD mice, isotype switching 
ensues after 2 to 3 weeks, with the autoAbs switching from IgM to IgG subclasses (Kaya et 
al. 2001; Kaya et al. 2002). It is particularly remarkable to note that the chronic 
autoimmune heart disease induced by coxsackievirus B3 in mice resembles inflammatory 
heart disease seen with myocarditis and dilated cardiomyopathy in humans.  There are 
still many complications with the full characterization and study of chronic virus and/or 
autoimmune induced myocarditis in mice and humans.  One such complication is the 
acute infection that precedes chronic disease.  
3. Experimental autoimmune myocarditis 
As described in the previous section, mouse models greatly aid the analysis of autoimmune 
diseases. To set apart the autoimmune phase of disease from acute infection an experimental 
induced autoimmune myocarditis model was developed (Blyszczuk et al. 2008). 
Experimental induced autoimmune myocarditis mimics the typical chronic phase of disease 
observed in genetically susceptible mice infected with coxsackievirus B and different stages 
of disease severity observed with experimental induced autoimmune myocarditis models 
are graded according to the extent of inflammatory infiltrates at the peak of inflammation.  
Autoimmune myocarditis can be induced by the injection of cardiac myosin with complete 
Freund’s adjuvant and pertussis toxin.  Mice injected with this combination of self- antigen 
and adjuvants are able to generate cardiac myosin-specific autoantibodies and present with 
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heart pathology similar to coxsackievirus B3-induced disease 3 weeks post-injection (Figure 
2) (Kodama et al. 1992).  
 
 
Fig. 2. Experimental autoimmune myocarditis versus coxsackievirus B3 induced 
myocarditis. Experimental autoimmune myocarditis involves the induction of 
autoimmunity by the injection of self-protein such as cardiac myosin or troponin I with 
adjuvants or without or injections of other cardiomyogenic peptides to induce chronic 
myocarditis as seen with coxsackievirus B3 infection in susceptible mice. 
Neu et al suggest that autoimmune myocarditis is induced indirectly by viral infection and 
that one causative factor may be an autoimmune response to the cardiac myosin released or 
exposed after the virus-mediated myocyte damage (Neu et al. 1987). If this is the case, 
autoimmune disease should be induced by immunization with cardiac myosin alone and 
susceptibility to coxsackievirus B3-induced autoimmune myocarditis should be as likely as 
susceptibility to the myosin-induced autoimmune disease (Neu et al. 1987). Troponin I has also 
been used as an autoantigen for induced autoimmune myocarditis (Leuschner et al. 2009). 
Programmed cell death-1 receptor deficient mice develop cardiomyopathy with production of 
high-titered autoantibodies against cardiac troponin I (Okazaki et al. 2003). Cardiac troponin I 
induces a robust autoimmune response that encompasses both humoral and cellular responses 
that leads to severe inflammation and fibrosis in the myocardium of mice. Mice induced with 
cardiac troponin I have a genetic and sex biased susceptibility for myocardial inflammation 
compared to other autoimmune disease models (Leuschner et al. 2009). The key to 
reproducing ideal autoimmune disease conditions for studying myocarditis is to use a defined 
immunogen, ie cardiac myosin, troponin I etc. obtained from the same species as the study’s 
model. Moreover, genetically defined inbred strains of susceptible and resistant mice allow 
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results to be reproducible and facilitate detailed analysis of the autoimmune disease cellular 
and molecular components (Neu et al. 1987). 
Other species such as rats and Guinea pigs have also greatly contributed to our 
understanding of myocarditis. Immunization of different animal models with heart 
homogenates derived from various species has not been, unfortunately, successful at 
inducing myocarditis, where the results were often controversial (Neu et al. 1987). In most 
of those models, mild lesions appeared in the heart. However, out of the differing species 
models, 2 reports: the guinea pig model by Hosenpud et al and the murine model by Neu et 
al, showed enlargement of the heart with autoimmune myocarditis (Hosenpud et al. 1985; 
Neu et al. 1987). The authors also noted discoloration of cardiac surfaces, pericardial 
effusion and lethal clinical course that were conditions not previously observed in 
experimental induced autoimmune myocarditis. Kodama et al were also able to produce 
such pathological and clinical conditions using the Lewis rat model (Kodama et al. 1992) 
though the cardiac myosin immunization murine model seems to have had the greatest 
impact on our understanding of autoimmune myocarditis.  
There are many ways in which autoimmune myocarditis can been induced in animal 
models. Immunization of susceptible mice with cardiac myosin or with a myocardiogenic 
peptide derived from the alpha cardiac heavy chain emulsified in complete Freund’s 
adjuvant induces myocarditis in mice with a peak of inflammation in the heart around day 
21. This inflammation observed with induced autoimmune disease is similar to that seen in 
the coxsackievirus B3 induced autoimmune myocarditis model during the chronic phase, 
however in this case, does not include the earlier complication of a pathogen infection. The 
immunization with cardiac myosin is associated with production of cardiac myosin-specific 
autoantibodies and cardiac myosin-specific T cells (Kodama et al. 1992; Godsel et al. 2001; 
Leuschner et al. 2009; Rose 2010). It has been demonstrated that the induction of disease by 
immunization with cardiac myosin can only be successful in genetically susceptible mice 
(Neu et al. 1987). We suggest that the complex genetics of the host therefore determines 
whether an infection will resolve or proceed to an adverse autoimmune outcome 
(Poffenberger et al. 2010). Identifying particular traits that favour susceptibility or resistance 
to an autoimmune incidence helps us understand how infectious diseases culminate in 
autoimmune disease.  Other methods used to induce autoimmune myocarditis include 
administration of 2 early, critical proinflammatory cytokines, IL1b and TNF-┙ and injection 
of mice with myosin in combination with CFA and additional lipopolysaccharide. Some 
groups have reported the induction of autoimmune myocarditis using immunization with 
porcine cardiac myosin (Wang et al. 1999). Interestingly, Wittner et al. produced myosin 
autoantibodies and myocarditis in rabbits using immunization with bovine heart myosin 
(Wittner et al. 1983). Daniels et al reported the development of a recombinant model of 
experimental induced autoimmune myocarditis, induced by immunization with a 68kDa 
fragment of cardiac myosin referred to as Myo4 (Daniels et al. 2008). Myo4 induces severe 
autoimmune myocarditis in A/J mice 21 days post immunization. The immune response to 
Myo4 immunization is characterized by Th1 and Th17 features. Myo4-experimental induced 
autoimmune myocarditis has advantages over other models in terms of immunogen 
production and the ability to measure antigen-specific functional immunity in ex vivo assays. 
Myo4 and other immunoantigen experimental induced autoimmune myocarditis provide a 
means to investigate epitope spreading and the effect on disease pathology as well as 
prophylactic and therapeutic treatment studies aimed at developing therapeutics to alleviate 
acute and chronic autoimmune myocarditis (Daniels et al. 2008). 
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Experimental induced autoimmune myocarditis is mediated by a CD4+ T cell immune 
response. Homing of cardiac myosin-specific CD4+ T cells into the myocardium is the first 
pathologic event observed with experimental induced autoimmune myocarditis. 
Subsequently, neurohumoral factors such as cytokines and chemokines are released in the 
myocardium. This then recruits various bystander inflammatory cells to cross vascular 
endothelial cell walls and enter the myocardium. In effect, blocking the recruitment of 
inflammatory mediators to the myocardium may present as a critical target for myocarditis 
therapy (Tanaka et al. 2011). Experimental induced autoimmune myocarditis development 
is also typically associated with elevated titers of heart-specific autoantibodies, though in 
rats and susceptible mouse strains the response depends on the induction and expansion of 
heart specific, autoreactive CD4+ T cells. In BALB/c mice, CD4+ T cells belong to a specific 
subset of IL-17 producing helper cells, i.e. Th17 cells  (Chang et al. 2008). With experimental 
induced autoimmune myocarditis, heart-infiltrating alpha-myosin-specific CD4+ Th17 cells 
are pathogenic and cause ongoing inflammation in the myocardium (Blyszczuk et al. 2008). 
Notably, autoimmune myocarditis induced by myosin can be reiterated in mice adoptively 
transferred with pathogenic CD4+ T lymphocytes (Sukumaran et al. 2011). In addition to T 
cells, passive administration of antimyosin monoclonal antibodies induces myocarditis in 
DBA/2 but not in BALB/c mice. DBA/2 mice are susceptible to passively induced disease 
due to the presence of myosin or a myosin like protein in their extracellular matrix. In 
addition to antibodies and T cells contributing to the pathogenesis of inflammatory 
myocardial lesions (Leuschner et al. 2009), injection of activated bone marrow (BM)-derived 
dendritic cells loaded with heart-specific self peptide can instigate disease pathogenesis 
(Kania et al. 2009). 
Autoimmune myocarditis can be induced experimentally by several means as is the case for 
protection from induced disease. Amelioration of disease has been demonstrated with oral 
administration of specific antigens in several autoimmune models (Gonnella et al. 2009). 
Protection from experimental induced autoimmune myocarditis has also been observed 
with many studies from Godsel et al (Godsel et al. 2001). They successfully administered 
syngeneic splenocytes covalently coupled with ethylene carbodiimide (ECDI) by 
intravenous injections to prevent and treat a number of autoimmune diseases in animal 
models. Initial application of this approach in humans has been fortunately successful. 
Godsel et al essentially demonstrate in animal models that coupled-cell tolerance is an 
effective approach for the prevention of myocarditis and may present as a useful antigen-
specific immunotherapy for treating myocarditis in humans (Godsel et al. 2001). Antigen-
specific peripheral tolerance induction also represents a powerful tool for dissecting the 
mechanisms involved in cardiac autoimmunity. Although myosin-specific tolerization is 
commonly used to prevent experimental induced autoimmune myocarditis, it is also 
important to note that tissue homogenates are equally useful. This approach has yet to be 
tested in other models of myocarditis including coxsackievirus myocarditis (Godsel et al. 
2001). Horwitz et al’s investigation in to cardiac myosin tolerance and protection from 
experimental induced autoimmune myocarditis conflicted with results presented in the 
Godsel et al studies (Horwitz et al. 2005). Since cardiac myosin is a major autoantigen in 
virus-induced myocarditis the question was asked whether inhibition of this autoantibody 
response to cardiac myosin could prevent destructive autoimmunity. In NOD mice, cardiac 
myosin-specific antibodies develop following both coxsackievirus B3 infection and 
experimental induced autoimmune myocarditis induction. To ask whether the induction of 
peripheral tolerance to a single self-antigen could be used to prevent coxsackieviral-induced 
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autoimmune myocarditis, a disease likely directed at multiple self-antigens, NOD mice were 
tolerized to cardiac myosin using a covalently coupled antigen approach and subsequently 
challenged with coxsackievirus B3. Cardiac myosin tolerance to effectively prevent 
coxsackievirus B3-mediated autoimmune myocarditis was not observed, possibly 
reprimanding cardiac myosin as a single autoantigen player in viral-mediated disease 
(Horwitz et al. 2005).  
Another possible player in viral-mediated disease as demonstrated with experimental 
induced autoimmune myocarditis may be multinucleated giant cells. Wang et al showed 
that the cardiac lesions in experimental induced autoimmune myocarditis are histologically 
similar to human myocarditis, with myocyte swelling, necrosis, and fibrosis that are 
accompanied by mononuclear cell infiltration consisting of granulocytes, macrophages, 
CD4+, CD8+ T cells, B cells and multinucleated giant cells (Wang et al. 1999; Blyszczuk et al. 
2008; Daniels et al. 2008). Also, the histological features observed in myocarditis induced by 
cardiac myosin are very similar to the description of active giant-cell myocarditis in humans 
(Wang et al. 1999; Blyszczuk et al. 2008). Therefore, it has been inferred that macrophage-
derived multinucleated giant cells, together with other inflammatory cells, are important 
mediators of myocyte destruction. The presence of a heterogeneous population of cellular 
components in the cardiac infiltrate also implies the existence of a complex, cytokine-rich 
microenvironment that may contribute to the pathogenesis of autoimmune myocarditis. 
TNF-┙, IL-1┚, IL-2, IFN-┛, IL-4 and IL-10 are cytokines that have been detected in culture 
supernatants of splenocytes derived from mice at the peak of myocardial disease. Their 
detected levels were higher in mice that developed myocarditis than mice immunized but 
not developing disease. Furthermore, it has been previously suggested that TNF-┙ 
contributes to myocarditis pathogenesis by either causing direct injury of cardiomyocytes 
or, together with IL1b, triggering the production of nitric oxide. The expression of E-selectin, 
VCAM-1 and ICAM-1 has also been found to be markedly increased in inflamed hearts 
during induced disease. The increased expression of these adhesion molecules on the 
vascular endothelium may contribute to the extravasation and accumulation of 
inflammatory cells observed in the myocardium (Wang et al. 1999; Blyszczuk et al. 2008).  
There are limitations of using experimental induced autoimmune myocarditis as a model to 
separate the mechanisms of biphasic (acute infection and chronic) viral disease, where the 
model relies too heavily on the inoculation of a single antigen.  There are undoubtedly other 
key immune players that contribute to the onset of autoimmune disease following virus 
infection with the innate immune system being one of the major contributors having a dual 
role: controlling and perpetuating disease. Despite the fact that the experimental induced 
autoimmune myocarditis models are rather artificial, they offer the advantage of studying 
disease pathogenesis and autoimmune mechanisms in vivo in the absence of an infective 
agent. Immunization with myosin peptide-loaded activated dendritic cells offers a useful 
tool to dissect the role of antigen-presenting cells (APCs) and effector cells while studying 
disease mechanisms. From the experimental induced autoimmune myocarditis model we 
can not only learn about autoimmune mechanisms contributing to disease development, but 
we can study the pathophysiology of inflammatory heart disease and design novel 
immunomodulating treatment strategies. In addition, the experimental induced 
autoimmune myocarditis model might offer a potential tool to improve the diagnostic 
accuracy of currently available and future imaging technologies (Blyszczuk et al. 2008). 
Work from our lab using the experimental induced autoimmune myocarditis model has 
helped focus our attention to the role of innate immunity in response to an infectious agent 
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and as a driving force in the development of autoimmune disease. The innate immune 
system includes many key players like pathogen recognition receptors that recognize highly 
conserved pathogen-associated molecular patterns on microbial invaders. These receptors 
include the Toll-like receptors and expression of these receptors on antigen presenting cells 
such as macrophages and dendritic cells determine not only innate immunity but the 
subsequent adaptive immune response. 
4. Key players in immunity 
4.1 Pathogen recognition receptors 
Cardiotropic viruses can be cytopathic, killing off host cells, yet their viral RNA is detected 
and tends to persist in cardiac muscle. Viral persistence in the myocardium can then lead to 
chronic inflammatory cardiomyopathy. Pathogens such as viruses are recognized by Toll-
like receptors (TLRs) and other pattern recognition receptors of the innate immune 
response. The recognition of a pathogenic insult releases proinflammatory cytokines that 
serve as protectors from infection and perpetrators of chronic inflammatory disease (Lane et 
al. 1993; Kawai et al. 2006). Activation of Toll-like receptors by pathogen associated 
molecular patterns and the subsequent production of proinflammatory cytokines can lead to 
protection as well as the exacerbation of an autoimmune response.  
Pathogen-associated molecular patterns from viruses like double-stranded RNA are sensed 
by Toll-like receptor 3 (TLR3) (Schnare et al. 2001; Pasare et al. 2003). Infections with 
coxsackievirus B in TLR3 knock out mice have demonstrated an important role for TLR3 in 
host defense. The innate antiviral response is mediated, at least in part, by nucleic acid-
sensing receptors such as TLR3, retinoic acid inducible gene I (RIG-I), and melanoma 
differentiation-associated protein-5 (MDA-5). The activation of RIG-I/MDA5 receptor 
pathways is thought to evoke type I IFN responses. TLR3, which recognizes double 
stranded RNA, is critical in the antiviral immune response against coxsackievirus B3. TLR3-
deficient mice are highly susceptible to coxsackievirus B3, where impaired antiviral 
responses and acute myocarditis ensue. Increased disease in TLR knock out mice is 
associated with decreased production of IL-12p40, IFN┛ and IL-1┚ post infection. Mice 
deficient in the TLR3 adaptor protein, Trif, have a similar disease course as TLR3 knock out 
mice suggesting that the TLR3-Trif pathway is also important in the host response to 
coxsackievirus B3 infection. Research from Negishi et al reveals a critical cooperation 
between the RIG-I/MDA5-type I IFN and TLR3-type II IFN signaling axes for efficient 
innate antiviral immune responses (Negishi et al. 2008). Importantly, a rare TLR3 variant 
has been identified in patients diagnosed with enteroviral myocarditis (Gorbea et al. 2010). 
These patients also held a greatly increased incidence of a common polymorphism. Gorbea 
et al also demonstrated that induction of the TLR3 variant or the TLR3 possessing the 
common polymorphism with synthetic double stranded RNA hindered proper TLR3-
mediated signaling. Also, with coxsackievirus B3 infected cell lines, mutated TLR3 impaired 
type I IFN signalling and production and failed to control viral replication (Gorbea et al. 
2010). The Gorbea et al study thus suggests that individuals who possess these particular 
TLR3 variants may have an ineffective innate anti-enteroviral response that fails to clear the 
virus and in turn, elevates the associative risk for cardiac disease. Interestingly, human 
cardiac myosin pathogenic epitopes can directly stimulate other human Toll-like receptors 
such as Toll-like receptors 2 and 8 (TLR2, TLR8). Stimulation of these receptors allows for 
the production of proinflammatory cytokines from human monocytes. TLR8, found within 
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endosomes, detects single stranded RNA, such as the coxsackievirus B3 genome and 
instigates inflammation (Triantafilou et al. 2005; Zhang et al. 2009). 
Signalling through another critical receptor, Toll-like receptor 4 (TLR4) also leads to the 
expression of proinflammatory cytokines, but has been implicated as a cardiomyopathy 
etiological factor. Satoh et al have suggested that myocardial expression of TLR4 is linked to 
coxsackievirus B3 replication in human cardiomyopathy and that TLR4 may be directly 
involved in the pathogenesis of disease  (Satoh et al. 2004). Viral proteins have actually been 
found to co-localize with TLR4 in infected cardiac tissue. In coxsackievirus B infected mice, 
TLR4 deficiency reduces viral pathogenesis and the production of several cytokines 
including IL-1┚ and IL-18 (Pasare et al. 2003; Pasare et al. 2004).  
Another major player in host defense is the critical adaptor protein for TLR signaling 
myeloid differentiation primary response gene (MyD88). MyD88 signaling has been 
associated with several aspects of the pathogenesis of chronic autoimmune myocarditis. 
MyD88 activates self-antigen presenting cells and promotes autoreactive CD4+ T-cell 
expansion in experimental induced autoimmune myocarditis. To determine the role of 
MyD88 in the progression of acute myocarditis to an end-stage heart failure, Blyszczuk et al 
used alpha-myosin heavy chain peptide (MyHC-alpha)-loaded activated dendritic cells 
(Blyszczuk et al. 2008). They induced myocarditis in wild-type and MyD88 knock out mice 
and observed comparable heart-infiltrating cell subsets and CD4+ T-cell responses. Injection 
of complete Freund’s adjuvant or MyHC-alpha/complete Freund’s adjuvant into diseased 
mice caused cardiac fibrosis, ventricular dilation, and disrupted heart function in wild-type 
but not MyD88 knock out mice (Pasare et al. 2003; Marty et al. 2006; Blyszczuk et al. 2008). 
The protection of MyD88 knock out mice from the induction of experimental induced 
autoimmune myocarditis is likely from the impairment of other key players of 
autoimmunity such as antigen presenting cells. The role of MyD88 in cardiac fibrosis has 
been demonstrated with chimeric mice, where the origin of fibroblasts that replace 
inflammatory infiltrates was determined to be from the bone marrow. MyD88 has thus been 
suggested to be critical for the development of cardiac fibrosis during progression to heart 
failure (Pasare et al. 2003; Marty et al. 2006). Fuse et al observed elevated MyD88 cardiac 
protein levels in the hearts of wild-type mice after exposure to coxsackievirus B3 and 
MyD88 knock out mice have a greater survival rate (86%) compared to wild type mice (35%) 
after coxsackievirus B3 exposure (Fuse et al. 2005). MyD88 is implicated not only in cardiac 
inflammation and mediating cytokine production, but is also associated with skewing the 
Th1/Th2 cytokine balance, increasing the expression of coxsackie-adenoviral receptor 
important for virus entry and viral titers after coxsackievirus B3 incidence. In the absence of 
MyD88, protection from virus infection and disease is observed and is suggested to be 
associated with IRF-3 and IFN-┚ activation (Fuse et al. 2005). From the above mentioned 
MyD88 work, it is fair to infer that MyD88 could be a useful target for preventative heart-
specific autoimmunity and cardiomyopathy treatments (Marty et al. 2006). TLR signalling 
may be a major contributor to the initiation and progression of autoimmune myocarditis 
though there are many additional players such as the cells that express viral and self antigen 
sensors (antigen presenting cells) that remain  poorly understood. 
4.2 Antigen presenting cells (APCs) 
Following viral infection, a cellular immune response is needed to completely clear the 
virus. However these same cells can drive chronic inflammation and autoimmune 
responses. Antigen presenting cells and other cell types critical in activating the cellular 
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response to viral infection such as CD4+ T cells, CD8+ T cells, ┛├ T cells, B cells, 
macrophages, mast cells, neutrophils, NK cells and DC cells are all detected in the hearts of 
mice post coxsackievirus B3 infection and with experimental induced autoimmune 
myocarditis induction (Afanasyeva et al. 2004; Cooper 2009; Kemball et al. 2010).  
Antigen presenting cells play a pivotal role in the stimulation of acquired immunity and can 
be manipulated by cytokines and environmental factors. The manipulation of antigen 
presenting cells modulates the T cell response and results in changes in tolerance to specific 
antigens. Antigen presenting cells influence lymphocyte responses by 1) promoting helper 
T-cell 1 (Th1), Th2 or Th17 responses, 2) inducing peripheral tolerance, and 3) activating 
regulatory T cells (Chatenoud et al. 2005; Ait-Oufella et al. 2006; Blyszczuk et al. 2008). From 
autoimmunity studies it has been curiously determined that regulatory T cells and Th17 
cells have opposing functions during autoimmunity (Langrish et al. 2005). Th17 cells are an 
important pro-inflammatory T cell lineage during heightened tissue inflammation and 
autoimmunity, whereas regulatory T cells cells function to suppress immune responses  
(Richer et al. 2008; Korn et al. 2009; Marchant et al. 2010; Wing et al. 2010; Zou et al. 2010). 
Antigen presenting cells trigger changes in regulatory T cells and other T cell populations, 
which alters disease outcome and may be a promising therapeutic avenue to further 
investigate in viral-induced autoimmune diseases such as viral myocarditis.   
Damage to the myocardium and the onset of coxsackievirus B3-induced acute myocarditis 
in mice is attributable to many immune factors including activated antigen-specific T cell 
activity. Two signals are required for activating T cells: first through the T-cell receptor 
engaging with antigen loaded MHC on antigen presenting cells and next through 
costimulatory molecules on antigen presenting cells such as CD40 and B7. CD40L on T cells 
engages CD40 on antigen presenting cells activating them to secrete cytokines and express 
adhesion molecules. Signalling from both the T cell receptor and costimulatory molecules 
promotes the proliferation of the antigen-specific T cells and stimulates an anti-antigen 
immune response. Early work with CD40/CD40L revealed enhanced CD40 expression on 
cardiac myocytes of coxsackievirus B3-infected mice and reduced myocardial inflammation 
with anti-CD40L/B7-1 monoclonal antibody treatment (Seko et al. 1998).  Increased 
expression of CD40 and the B7 family of costimulatory molecules has also been observed in 
myocardial tissue from patients with dilated cardiomyopathy and acute myocarditis  (Seko 
et al. 1998). Recently, CD40-Ig treatment was used post-coxsackievirus B3 infection to block 
the interaction between CD40/CD40L in male Balb/c mice and notably, this treatment 
reduced inflammation and coxsackievirus B3 transcription. CD40-Ig treatment also skewed 
the Th1/Th2 response in favour of Th2 cytokines rather than Th1 (Bo et al. 2010). This work 
and studies with myocardial tissue from patients has important implications not only for the 
role of CD40, but also for potential therapeutic options that downregulate the inflammatory 
Th1 response in coxsackievirus B3-mediated acute myocarditis.  
Dendritic cells are highly specialized antigen presenting cells that upon encountering a 
pathogen undergo maturation. This process involves antigen processing, upregulation of 
major histocompatibility class (MHC) class II molecules, induction of costimulatory 
activity and migration to lymph nodes, where they prime antigen-specific T cells. With 
their antigen processing capability, dendritic cells can trigger activation of autoreactive T 
cells (Eriksson et al. 2003). Dendritic cells may also be involved in both host defense and 
maintenance of peripheral tolerance. Dendritic cells may also play an important role in 
autoimmune myocarditis (Marty et al. 2006). Dendritic cells from infected susceptible 
mice produce lower levels of cytokines and chemokines, particularly IP-10, a chemokine 
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with cardioprotective properties. In the hearts of healthy wild type mice, tissue-resident 
dendritic cells take up and present endogenous heart-specific peptides (Eriksson et al. 
2003). Activated and self-antigen loaded dendritic cells induce myocarditis and heart 
failure in genetically susceptible mice. The mechanism by which dendritic cells instigate 
damage to the myocardium is likely a combined effect from tissue damage and innate 
immunity activation that causes dendritic cells to activate autoreactive T cells and target 
the myocardium (Marty et al. 2006). This proposed mechanism was supported by 
Eriksson et al who have shown that injection of dendritic cells loaded with cardiac myosin 
peptide induces CD4+ T-cell-mediated autoimmune myocarditis (Eriksson et al. 2003). 
Interestingly, the dendritic cell-induced autoimmunity observed by Eriksson et al resulted 
only with TLR and CD40 stimulation. They demonstrated how TLR signalling following 
the onset and resolution of acute myocarditis instigates the reoccurrence of inflammatory 
infiltrates in the heart and the onset of autoimmunity.  TLR signalling activation was also 
important for myocarditis induction in mice injected with damaged, immune stimulating 
cardiomyocytes (Eriksson et al. 2003).  These few studies provide an insight into the 
possible role of dendritic cells in the induction of myocarditis and they offer an 
alternative, complete Freund’s adjuvant-free method of inducing experimental induced 
autoimmune myocarditis (Afanasyeva et al. 2004). 
The work done by Eriksson et al suggests targetting TLR signalling pathways may be 
needed as a therapeutic avenue to protect from heart-specific autoimmunity. In a scenario 
where microbial infections are acting concurrently with myocardial damage, such as with 
coxsackievirus B3 infection and myocarditis onset, self peptide–loaded dendritic cells might 
respond to the various pathogen associated molecular patterns in the environment that 
stimulate different TLRs and induce tolerance rather than act in antigenic mimicry. The end 
result may not be antigenic mimicry to instigate autoimmunity, but  downregulation of 
autoreactive T cells and induction of tolerance (Eriksson et al. 2003; Blyszczuk et al. 2008). 
With this in mind, innate activation pathways such as TLR signaling, may be attractive 
targets for autoimmune myocarditis therapy. 
Macrophages, another type of antigen presenting cell, play a critical role in the immune 
response to coxsackievirus B3 infection and have been implicated in the pathogenesis of 
coxsackievirus B3-induced autoimmune myocarditis. There are two groups of macrophages, 
type I or type II that are defined by their activation markers and cytokine production. Type 
II macrophages have been linked to the cardiac repair stage following acute myocarditis  
(Nahrendorf et al. 2007). The significance of macrophages in coxsackievirus B3 myocarditis 
was demonstrated in previous work by Richer et al and Horwitz et al, where a transgenic 
TGF-┚ mouse model demonstrated a protective role for TGF-┚ against autoimmune disease. 
This protection coincided with a reduction in macrophage maturation suggesting the 
important involvement of macrophage inflammatory properties (Horwitz et al. 2006; Richer 
et al. 2006).  It has been suggested therefore, that a balance between the inflammatory 
macrophages that are necessary for defense against viruses and the macrophages necessary 
for the resolution of an immune response and tissue healing is critical for an appropriate 
antiviral immune response that avoids autoimmunity  (Heath et al. 2004).  Interestingly, 
macrophage phenotype can differ between male and female mice with coxsackievirus B3-
induced myocarditis. Since coxsackievirus B3 infection induces severe myocarditis only in 
male mice it is possible that myocardial infiltrating macrophages detected in female mice 
will have a distinct functional phenotype that contributes to their protection from 
coxsackievirus B3-induced myocarditis. Li et al observed myocardial infiltrating 
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macrophages from coxsackievirus B3-infected male mice expressing high levels of classically 
activated macrophages (type I) markers, such as inducible nitric oxide synthase, IL-12, TNF-
┙, and CD16/32, whereas macrophages from females had increased expression of arginase 
1, IL-10, macrophage mannose receptor and macrophage galactose type C-type lectin  that 
are typically associated with alternatively activated macrophages (type II) (Li et al. 2009).  Li 
et al also demonstrated a distinct myocardial-derived cytokine signature that is sex-biased 
and contributes to differential macrophage polarization after coxsackievirus B3 infection. 
With adoptive transfer experiments using ex vivo programmed M1 macrophages, Li et al 
observed significantly increased myocarditis in both male and female mice. However, the 
transfer of M2 macrophages into susceptible male mice protected mice from myocardial 
inflammation (Li et al. 2009). This protection was postulated to be the result of a modulated 
local cytokine profile that contributed to the promotion of peripheral regulatory T cells 
differentiation. This work has helped our understanding of a possible mechanism that 
underlies the gender bias in coxsackievirus B3 myocarditis susceptibility.  Developing 
therapeutic strategies that manipulate macrophage polarization may be a promising avenue 
for the treatment of inflammatory heart diseases.  
4.3 Cytokines and chemokines 
Cytokines and chemokines also play critical roles in the detection of pathogens and the 
response by the innate immune system. Unfortunately, they are also actively involved in the 
pathogenesis and progression of viral myocarditis. Transgenic mouse models expressing 
cytokines have facilitated our understanding of interplay between cytokines at the sites of 
infection and the development of autoimmune disease.  
During experimental induced autoimmune myocarditis, it has been thought that CD4+ Th 
cells differentiate into IL-2- and IFN┛-producing Th1 and IL-4-, IL-10- and IL-13-producing 
Th2 cell subsets and that the balance in T-helper cytokines can influence susceptibility and 
outcome of myocarditis (Horwitz et al. 2000). In recent research, it has been revealed that IL-
1, IL-6, and IL-23 promote the differentiation of a distinct CD4+ T cell population that 
produces IL-17 and develops independently of Th1 and Th2 lineages (Blyszczuk et al. 2008). 
This new population denoted Th17, plays an important role for various models of immune-
mediated tissue injury, including organ-specific autoimmunity diseases like myocarditis 
(Horwitz et al. 2000).  
Work from our laboratory has established a critical link between IL-6 and disease severity. 
Work done by Poffenberger and colleagues has shown a significant increase in disease 
severity with the absence of IL-6 after coxsackievirus B3 infection in mice. An increase in 
inflammatory mediators associated with the progression of myocarditis such as TNF-┙ and 
MCP1 was observed in concordance with the increase in disease severity (Poffenberger et al. 
2009). Without IL-6 to regulate the early immune response after infection, the early 
inflammatory response leads to increased chronic myocarditis severity as the disease 
progresses (Poffenberger et al. 2009).  
An important factor affecting the immune response to the virus and viral clearance is the 
pro-inflammatory cytokine interferon-┛ (IFN┛). Coxsackievirus B3 infection in mice 
deficient in IFN┛ results in increased disease severity and increased viral replication in the 
heart (Eriksson et al. 2001; Fairweather et al. 2005). Expression of IFN┛ in the pancreas can 
control viral replication as well as the virus-mediated damage in the heart and ensuing 
autoimmune disease (Horwitz et al. 2000). This cytokine also controls disease severity in an 
adjuvant induction disease model. In essence, IFN┛ likely limits myocarditis pathology by 
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decreasing viral replication and virus-mediated damage. Resolution of inflammation and 
progressive remodeling are associated with high levels of another cytokine transforming 
growth factor-┚ (TGF-┚) in the myocardium.  
TGF-┚ is a pleiotropic, immunomodulating cytokine that greatly contributes to myocardial 
repair and remodelling (Khan et al. 2006; Rubtsov et al. 2007). Cardiac fibroblasts are the 
predominant source of secreted TGF-┚ within the heart. Secretion of TGF-┚ drives 
differentiation of cardiac fibroblasts into their more active myofibroblast form (Lijnen et al. 
2002). It is with this active connective tissue cell form and stimulation by TGF-┚ that copious 
amounts of collagen can be secreted (Petrov et al. 2002). Fibrillar collagen is a leading 
contributor to extensive fibrosis. With disproportionate amounts of secreted collagen, 
ventricles tighten, restricting proper diastolic function (Kania et al. 2009). TGF-┚ contributes 
to the secretion of collagen via the TGF-┚-Smad pathway that promotes collagen gene 
activation and translation (Khan et al. 2006).  TGF-┚ also enhances the production of 
adhesion molecules that in turn, promote the longevity of myofibroblasts (Vaughan et al. 
2000). Macrophages also secrete TGF-┚ in the heart (Riemann et al. 1994). They colocalize 
with myofibroblasts in fibrotic heart tissue and act as either initiating or supplemental 
sources of TGF-┚1 (Hinglais et al. 1994; Kuwahara et al. 2004).   
Coxsackievirus B3 first targets and replicates in the pancreas before reaching the heart. To 
inhibit coxsackievirus B3 spread to the heart and initiation of chronic disease, Horwitz et al 
developed a transgenic TGF-┚ mouse model where TGF-┚ is overexpressed in the pancreas. 
The expression of TGF-┚ in the pancreatic beta cells recruited macrophages into the 
pancreas, reduced viral replication, and inhibited the onset of coxsackievirus B3-induced 
autoimmune myocarditis. This study also demonstrated that the protective effect was 
strictly attributed to TGF-┚ and not IL-4, which has been linked to both autoimmunity 
suppression and antigen-presenting cell activation (Horwitz et al. 2006). Later on, Richer et 
al demonstrated that LPS from Salmonella minnesota and signalling through TLR-4 was 
capable of bypassing the protective effect provided by TGF-┚ in coxsackievirus B3-mediated 
autoimmune myocarditis (Richer et al. 2006). The authors also showed that neither antibody 
isotype switching, the extent of viral replication, nor the expression of CD40 was modulated 
with LPS induced TLR-4 signalling, rather the circumventing effect was due to failed APC 
expression of CD40 and inherent TLR-4 signalling effects such as the production of pro-
inflammatory cytokines (Richer et al. 2006).             
Though over-expression of TGF-┚ in the pancreas can protect from coxsackievirus B3-
induced autoimmune myocarditis, there is still evidence that increased levels of TGF-┚1 in 
the heart enhance, rather than protect from chronic disease. Elevated levels of TGF-┚ have 
also been tied to dilated, ischemic and hypertrophic cardiomyopathies (Khan et al. 2006). As 
mentioned previously, TGF-┚ can enhance collagen secretion and thus promote extensive 
tissue fibrosis. A recent study examined the effect of astragaloside IV, a Chinese medical 
herb that has anti-myocardial injury and immunoregulatory properties, to inhibit 
myocardial fibrosis in Balb/c mice inoculated with coxsackievirus B3 (Chen et al. 2011).  
Interestingly, astragaloside IV exhibited a protective effect alike TGF-┚ against myocardial 
fibrosis and significantly ameliorated survival in coxsackievirus B3-infected mice that 
developed dilated cardiomyopathy. The authors also suggest that the protective role exerted 
by astragaloside IV is likely due to its ability to interfere with TGF-┚-Smad signalling 
through the direct downregulation of Smad2/3 and Smad 4 (Chen et al. 2011).      
Lipopolysaccharide injection at the time of coxsackievirus B3 infection helps overcome 
genetic resistance in susceptible mice. This investigation also identified interleukin (IL)-1 as 
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the mediator responsible for causing the change in disease course. Injection of IL-1 alone 
overcomes the genetic resistance to induced myocarditis similarly to lipopolysaccharide 
treatment. The change in disease susceptibility is likely due to increased IL-1 production in 
the heart. Production of IL-1 begins during the acute stage of disease but persists into the 
chronic phase of disease. Interestingly, the levels of IL-1 in the heart correlate with the 
degree of fibrotic lesions during disease. Eriksson et al demonstrated that injection of an IL-1 
receptor agonist prior to infection sufficiently decreases viral titres in the heart and reduced 
chances of mortality. They also showed that IL-1 receptor stimulation is required for 
efficient dendritic cell activation, the subsequent induction of autoreactive CD4+ T cells, and 
resulting autoimmune disease (Eriksson et al. 2003). 
Another important immunomodulating cytokine that contributes to viral-induced 
myocarditis and controls macrophage activation is IL-10. IL-10 is produced in the 
myocardium during both the acute and chronic stages of virus-induced myocarditis. 
Chronic coxsackievirus B3-induced myocarditis features viral RNA persistence and chronic 
inflammation that is primarily mediated by macrophages and T cells therefore, cytokines 
like IL-10 that control these critical immune cells are important to investigate. IL-10 gene-
deficient mice have been used to confirm the regulatory role of IL-10 in the outcome of 
coxsackievirus B3 myocarditis. Mice deficient in IL-10 have uncontrolled nitric oxide 
synthase production, which likely contributes to their ongoing myocardial injury (Szalay et 
al. 2006). IL-10 in experimental induced autoimmune myocarditis mice hearts is mainly 
detected in non-cardiomyocytic non-inflammatory cells (ie. fibroblasts, smooth muscle cells, 
and endothelial cells) and IL-10-targeting cells. The IL-10-targetting cells, which express 
both IL-10 receptors 1 and 2, are mainly T cells expressing ┙┚T cell antigen receptors (┙┚T 
cells) and CD11b+ cells such as macrophages, dendritic cells, and granulocytes. Several 
studies have demonstrated a therapeutic effect for IL-10 in autoimmune and inflammatory 
diseases. In myocarditis models, IL-10 has been shown to inhibit the secretion of 
proinflammatory cytokines such as TNF-┙, IFN-┛, iNOS, IL-2 and IL-12 and has displayed 
major effects on immune cells (Horwitz et al. 2000). These few studies suggest that the role 
of IL-10 in disease development could be predominantly protective. 
IL-12, another key cytokine, is comprised of p40 and p35 subunits.  IL-12 signals through a 
heterodimeric receptor composed of two units, IL-12R┚1 and IL-12R┚2. p40 and IL-12R┚1 
deficient mice show less or no myocardial disease with adjuvant-induction and treatment of 
wild type mice with IL-12, exacerbates disease suggesting IL-12 as a driving force in disease 
development similar to the actions of IL-1┚ and TNF┙ (Eriksson et al. 2001; Afanasyeva et al. 
2004). However, Fairweather et al have found that IL-12 deficiency does not prevent 
myocarditis, rather viral replication significantly increases, causing more myocardial tissue 
damage. A decrease in inflammatory infiltrates was also observed and corresponded to with 
reduced TNF-┙ and IFN-┛ levels in the heart. IL-12 and IFNg positively regulate each other 
and type I inflammatory responses. Type I inflammatory responses are believed to be 
responsible for tissue damage in autoimmune diseases. Eriksson et al further investigated the 
role of the IL-12/IFN-┛ (Th1) axis in the development of autoimmune myocarditis. They 
observed resistance to disease in IL-12p40-deficient mice that were bred on a susceptible 
background. In the absence of IL-12, they suggested that autospecific CD4+ T cells proliferated 
poorly and exerted Th2 cytokine responses. IFN-┛-deficient mice developed fatal autoimmune 
disease. Interestingly, blocking IL-4R signalling did not confer susceptibility to myocarditis in 
IL-12p40-deficient mice. This suggests that IL-12 triggers autoimmunity in a manner 
independent of the cytokines IFN-┛ and IL-4 (Eriksson et al. 2001).  
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IL-13 is another cytokine that can protect mice from both viral and adjuvant induced 
myocarditis. Cihakova et al demonstrated that IL-13 knock out BALB/c mice develop severe 
autoimmune myocarditis and their pathology is characterized by increased cardiac 
inflammation, increased total intracardiac CD45+ leukocytes, elevated anti-cardiac myosin 
autoantibodies, and increased cardiac fibrosis, with impaired cardiac function and heart 
failure. Hearts of IL-13 knock out mice showed elevated levels of the proinflammatory and 
profibrotic cytokines including IL-1┚, IL-18, IFN-┛, TGF-┚, and IL-4. CD4+ T cells were also 
highly increased in IL-13 knock out hearts. Splenic T cells from the knock out mice were 
greatly activated and with myosin stimulation, immensely proliferated. Regulatory T-cells 
harvested from spleens were also affected in knock out mice, where they showed a decrease 
in numbers compared to wild type mice. IL-13 knock out also reduced alternatively 
activated CD206(+) and CD204(+) macrophages and hightened levels of classically activated 
macrophages. Caspase-1 activation was increased, which then likely increased production of 
both IL-1┚ and IL-18. This study exemplified IL-13 as another important 
immunomodulating cytokine that protects against myocarditis by manipulating T cell and 
macrophage populations (Cihakova et al. 2008). 
Examining T cells subsets is another avenue investigated to determine pathogenic or 
protective factors in myocarditis development. Mice deficient in T-bet, a T-box transcription 
factor required for Th1 cell differentiation and IFN-┛ production, develop severe 
autoimmune heart disease. T-bet can also regulate autoimmunity by controlling nonspecific 
CD8+ T cell bystander functions in the inflamed target organ such as the heart. CD4+ Th1 
cells producing INF┛ are protective in experimental induced autoimmune myocarditis. This 
protection is likely attributed to regulation of IL-17 production by Th17 cells. Th17 cells 
produce IL-17, a proinflammatory cytokine that activates T cells and other immune cells to 
produce a variety of cytokines, chemokines and cell adhesion molecules. Rangachari et al 
have shown that Th17 cells are involved in acute viral myocarditis and enhance humoral 
responses (Rangachari et al. 2006). The relationship between Th17 cells and coxsackievirus 
B3 replication still remained unclear so they infected BALB/c mice with the virus and 
observed increased viral replication, expression of splenic Th17 cells, serum IL-17, and 
cardiac IL-17 mRNA that were all accompanied by progressive cardiac injury. Interestingly, 
Th1 and CD8+ T cell expression was elevated and the neutralization of IL-17 further 
upregulated splenic Th1 and CD8+ T cell numbers and levels of cardiac IFN-┛ mRNA. 
Cardiac pathology was improved after IL-17 neutralization and correlated with reduced 
viral replication and decreases in cardiac inflammatory cytokines IL-17, TNF-┙, and IL-1┚. 
This study implicates Th17 cells in contributing coxsackeivirus B3 replication in viral 
myocarditis, and implicates IL-17 as a target for regulating antiviral immune responses 
(Yuan et al. 2010). Th17 cells are activated by IL-23, a cytokine likely produced by activated 
macrophages and dendritic cells, through receptor interactions made of IL-12R┚1 and IL-23 
receptor (Langrish et al. 2005). IL-23 is a heterodimeric cytokine like IL-12 that is composed 
of a p19 and p40 subunit similar to IL-12. IL-23–mediated immune responses have a 
different gene expression pattern than IL-12–driven T cell responses and IL-23 does not 
promote the development of IFN-┛-producing Th1 cells as does IL-12. IL-23 is however, one 
of the many contributors to pathogenic CD4+ T cell expansion. With its anti-IFN-┛ and Th1 
cell activity, IL-23 helps establish and maintain organ-specific inflammatory autoimmune 
diseases such as myocarditis (Langrish et al. 2005). Understanding the molecular basis for 
the differential gene expression pattern observed with IL-23–dependent T cell populations 
and investigating IL-23’s cellular mechanism of action in autoimmunity could provide 
additional therapeutic targets for the treatment of inflammatory autoimmune diseases. 
www.intechopen.com
 
Myocarditis 
 
260 
Experimental and preliminary human studies have demonstrated that TNF-┙ plays a crucial 
role in viral-induced myocarditis. Calabrese et al investigated the expression of TNF-┙ and 
both its receptors (TNFRI and TNFRII) in both viral and non viral myocarditis. Expression 
of TNF-┙ was significantly enhanced in viral myocarditis compared to non viral 
myocarditis. Importantly, cardiac myocytes express TNF┙ receptors TNFR1 (TNFRp55) and 
TNFR2 (TNFRp75), implicating the possible importance of enhance TNF-┙ in the 
myocardium. Histological analysis revealed that myocardial necrosis and cellular 
infiltration are more prominent in TNF-┙-positive cases further supporting the notion that 
the expression of TNF-┙ significantly contributes to the pathogenesis of viral myocarditis 
and including the severity of cardiac dysfunction (Calabrese et al. 2004). 
Chemokines act as chemotactic mediators in leukocyte trafficking to sites of infection 
(Groom et al. 2011). In addition to their chemo-attractant activity, chemokines can influence 
disease severity by modifying immune response strength and polarity. This immune 
modulating capability thus makes them attractive targets for viral myocarditis therapeutics. 
Chemokines apart of the CC chemokine family such as CCL2, CCL4, and CCL19 have been 
shown to mediate mononuclear cell migration to the heart in coxsackievirus B3-induced 
myocarditis (Chen et al. 2009). In fact, a recent gene therapy approach using a CCL2 mutant 
that lacked chemo-attractant activity in a Balb/c coxsackievirus B3-infection model impaired 
appropriate Th1 immune responses and significantly controlled myocardial disease (Yue et 
al. 2011). Blocking CCL2 with expression of the mutant did not assist in viral clearance. The 
potential therapeutic effect of blocking CCL2 lies in the CCL2 mutant’s ability to weaken the 
pro-inflammatory Th1 immune response (Yue et al. 2011).  
The CDC family of chemokines also contribute to myocarditis pathogenesis. CDC chemokines 
act on monoculear CXCR3 expressing cells and include such members as IFN-inducible 
protein 10 (IP10/CXCL10), monokine induced by IFN-┛ (Mig/CXCL9), and IFN-inducible T-
cell a chemoattractant (I-TAC/CXCL11) (Groom et al. 2011).  CXCL10 and its interaction with 
its receptor CXCR3 have been implicated in many virus disease models. CXCL10 is a key 
contributor in the innate immune response to viral infection. By interacting with its receptor 
CXCR3, CXCL10 manipulates natural killer cell trafficking and their production of IFN-┛. 
Yuan et al recently found CXCL10 levels in the heart to be inversely related to viral titers after 
coxsackievirus B3 infection and a massive infiltration of CXCR3+, CD4+, and CD8+ cells (Yuan 
et al. 2009). The production of associated inflammatory cytokines followed with the infiltration 
of leukocytes though the anti-viral response was not effective in clearing the virus or ensuring 
survival in coxsackievirus B3-infected CXCL10 transgenic mice (Yuan et al. 2009). CXCL10 did 
assist viral clearance and protect myocytes from damage in the early stages of infection by 
robustly attracting NK cells and enhancing IFN-┛ production to infection sites (Yuan et al. 
2009). Though CXCL10 appears to improve cardiac pathology and reduce viral persistence 
during initial infection stages, the caveat with using this chemokine as a potential 
coxsackievirus B3-induced myocarditis therapy lies with its inherent actions as a Th1-type 
chemeokine. Th1 immune responses escalate detrimental cardiac fibrosis during the 
reclamation stage of disease so enhancing important contributors to this repair process may 
acceleration rather than prevent the development of chronic disease.  
Determining the effect of CXCL10 on viral replication and recruitment of innate immune 
cells in other organs than the heart such as the liver and pancreas must still be pursued. As 
seen with another immunomodulatory factor, TGF-┚, the immune responses in other organs 
than the heart can affect susceptibility to severe myocardial injury and the development of 
chronic disease.        
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Recent research has demonstrated that coxsackievirus B3-infected Balb/c mice have 
increased levels of cardiac CXCL10 and this level fluctuates in a time and dose-dependent 
manner (Yue et al. 2011). The same research group treated coxsackievirus B3-infected mice 
with a CXCL10 mutant that lacks the critical chemo-attractant part. This mutant effectively 
blocked endogenous CXCL10 activity and protected coxsackievirus B3-infected mice from 
developing myocarditis (Yue et al. 2011). The CXCL10 mutant expressing mice had greater 
survival, less changes in body weight, less inflammation and necrosis in the heart. Cardiac 
Th1 cytokines IFN-┛, IL-12, TNF-┙, were also found to be significantly reduced with 
CXCL10/CXCR3 signalling inhibition. This suggests that dampening the Th1 response to 
coxsackievirus B3 infection through blocking CXCL10 activity may present as an effective 
strategy to suppress immune inflammation and myocardial damage in coxsackievirus B3-
mediated myocarditis (Yue et al. 2011).    
The production of immunomodulating mediators such as cytokines and chemokines affects 
not only antigen presenting cell and T cell populations acting at the site of injury, but greatly 
influences the outcome of disease. The expression of particular cytokines and chemokines 
after a pathogenic insult, such as coxsackievirus B3 infection, influences the balance of 
effector versus regulatory responses that ensue. Once the balance between effector versus 
regulatory responses tips in a particular direction, chronic autoimmune-type disease or the 
prevention of disease will materialize (Rouse et al. 2010; Wing et al. 2010) (Figure 3). It is 
therefore critical to bear in mind the possibility of tipping the immunity balance when 
manipulating key immune players in coxsackievirus-induced myocarditis.  
 
 
Fig. 3. Immunomodulation of the immune balance and the effects on disease outcome. With 
coxsackievirus B3 infection, populations of regulatory and effector cells are produced. It is 
with particular immunomodulating mediators such as cytokines interferon (IFN) and tumor 
necrosis factor (TNF) that enhanced production and proliferation of effector T cells  (Teff) is 
promoted and leads to the persistent destruction of the myocardium and chronic 
myocarditis disease. Pro-regulatory cytokines transforming growth factor-┚ (TGF-┚) and 
interleukin-10 (IL-10) are examples of immune modulators that promote the enhanced 
production of regulatory T cells (regulatory T cells) and the prevention of autoimmune 
myocarditis disease. 
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5. Therapeutic challenges and future directions 
Treatment for myocarditis mainly involves targeting the symptoms of heart dysfunction. If 
the disease progresses to dilated cardiomyopathy, heart transplantation is necessitated. 
Regrettably, for 50% of patients progressing to dilated cardiomyopathy, survival is limited 
to 5 years. Broad-spectrum antivirals tested in clinical trials with children and adults have 
been few and mildly successful. Specific therapies designed against viruses (enteroviruses) 
for prevention and/or management of viral myocarditis are still desperately needed.  One 
challenge in designing specific antivirals or vaccines for viral myocarditis is the range of 
possible etiologies and immune mechanisms that may be responsible. Although enteroviral 
infection inducing or exacerbating an autoimmune response is a likely cause for viral 
myocarditis, supporting data defining a link between viral infection and the onset of acute 
and/or chronic myocarditis in humans must still be determined. The existence of many viral 
serotypes for promising etiological agents like coxsackievirus B also poses a problem in 
designing specific antiviral therapies.  
Dampening the Th1 immune response in viral myocarditis is a therapeutic avenue 
consistently featured in past and recent studies. Many key innate immune players, such as 
cytokines and chemokines, are targets of potential Th1 skewing therapeutics. Cytokines 
presenting at the site of viral infection have a significant influence on whether a tolerant or 
autoimmune response is chosen. Targeting cytokines, chemokines and other 
immunomodulating factors for myocarditis therapy may depend on the timing and 
duration of the particular factor and the maintenance of immune balance to prevent the 
development of autoimmunity. 
6. Conclusion 
For quite some time scientists have investigated virus and host cellular and molecular 
events that underlie the pathogenesis of enteroviral-induced myocarditis. Our lab has 
demonstrated the significance of many key innate players that contribute to coxsackievirus-
B3 induced myocarditis in mouse models. Horwitz et al first revealed the importance of 
IFN-┛ expression in the pancreas for the protection from coxsackievirus B3 infection and the 
induction of myocarditis (Horwitz et al. 2000).  Later on, Horwitz et al again demonstrated a 
protective role against coxsackievirus B3-induced myocarditis with cytokine expression in 
the pancreas, this time, with transgenic expression of TGF-┚ in the beta cells (Horwitz et al. 
2006).  This work was followed by Richer et al, who provided a role for TLR4 and 
stimulation by Salmonella minnesota lipopolysaccharide in bypassing the protective effect 
exerted by TGF-┚ in coxsackievirus B3-induced myocarditis (Richer et al. 2006). Our lab has 
also investigated the role of IL-6 in disease severity. Poffenberger et al demonstrated that in 
the absence of IL-6, a greater early immune response occurred, instigating a severe chronic 
disease pathology (Poffenberger et al. 2009). Recently, Poffenberger et al described 
susceptibility loci on chromosome 17 that implicate the highly suggested genetic component 
as a factor dictating viral myocarditis pathogenesis (Poffenberger et al. 2010). Though work 
from our lab has contributed a great deal to the understanding of coxsackievirus B3-induced 
myocarditis, there remains many unanswered questions with regards to the true key 
immune players that dictate disease pathogenesis. It is likely that an interplay of genetic and 
environmental factors influence the susceptibility and severity of virus-induced myocarditis 
however, we must not discount the significance of the innate immune response in shaping 
the outcome of virus-induced disease. It is possible that this early immune response may 
www.intechopen.com
 
The Key Players of Coxsackievirus-Induced Myocarditis 
 
263 
ultimately dictate whether an acute or chronic immune response ensues with enteroviral 
infection.   
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